BRNS: the balance sheet

MyFinsight

For the quarter ending 2025-09-30, BRNS has $109,201K in assets. $24,640K in debts. $74,272K in cash and cash equivalents.

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Balance Sheets	2025-09-30	2025-06-30
Cash and cash equivalents	74,272	86,259
Restricted cash	1,402	1,525
Research and development incentives receivable	4,633	4,536
Prepaid expenses and other current assets	6,336	7,681
Assets held for sale	138	413
Total current assets	86,781	100,414
Property and equipment, net	4,519	4,514
Intangible assets, net	14,909	20,366
Right of use assets, net	2,063	3,323
Other assets	929	944
Total assets	109,201	129,561

Accounts payable	698	1,800
Accrued expenses and other current liabilities	6,681	7,364
Deferred income	1,402	1,525
Operating lease liability - current	2,017	2,036
Total current liabilities	10,798	12,725
Operating lease liability - non-current	9,553	9,952
Contingent consideration	2,508	2,544
Other non-current liabilities	1,461	1,468
Deferred tax liability, net	320	391
Total liabilities	24,640	27,080
Ordinary shares, 0.000025 nominal value 40,827,263 shares authorized, issued and outstanding (december31, 2024 authorized, issued and outstanding 40,234,663)	1	1
Deferred a shares, 1 nominal value 63,443 shares authorized, issued and outstanding (december31, 2024 authorized, issued and outstanding 63,443)-Deferred Shares.	86	86
Additional paid-in capital	393,248	393,663
Accumulated deficit	-293,002	-278,436
Accumulated other comprehensive loss foreign currency translation adjustments	-15,868	-12,937
Total stockholders equity attributable to barinthus biotherapeutics plc shareholders	84,465	102,377
Noncontrolling interest	96	104
Total stockholders equity	84,561	102,481
Total liabilities and stockholders equity	109,201	129,561